Active Ingredient(s): Nusinersen
FDA Approved: * December 23, 2016
Pharm Company: * BIOGEN
Category: Neurological Disorders

Nusinersen,[3] marketed as Spinraza,[1] is a medication used in treating spinal muscular atrophy (SMA), a rare neuromuscular disorder.[4][1] In December 2016, it became the first approved drug used in treating this disorder. Since the condition it treats is so rare, Nusinersen has so-called “orphan drug” designation in the United States and the European Union.[5] Contents 1 Medical uses 2 Side effect... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Spinraza 2.4 mg/ml Intrathecal Injection, Solution
NDC: 64406-058